Get the app
US › Healthcare

Heron Therapeuti (HRTX)

US · Healthcare · Biotechnology

$0.36-4.12%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$37.7M
Revenue YoY
+1.3%
Net profit
$-5.5M
EPS
$-0.03
EPS estimate
$-0.02
Net margin
-14.6%

EPS came in at -0.03 against a street estimate of -0.02 — a miss of 50.0%.

Key statistics

Market cap
$74.2M
Forward P/E
46.9
P/B
9.43
Book value
$0.03
EPS (TTM)
$-0.18
52-week high
$1.57
52-week low
$0.26
50-day MA
$0.34
200-day MA
$0.77
Beta
1.62

Analyst view

Analysts rate Heron Therapeuti a hold (0 buy, 2 hold, 0 sell out of 2) with an average price target of $7.00.

Shareholding

Insiders
0.98%
Institutions
70.25%

Largest institutional holders

FundStake
Rubric Capital Management LP15.83%
Clearline Capital LP6.00%
BlackRock Inc5.56%
Velan Capital Investment Management LP4.61%
Vanguard Capital Management, LLC4.10%
Tejara Capital Ltd3.43%
TANG CAPITAL MANAGEMENT LLC3.29%
Geode Capital Management, LLC2.25%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Heron Therapeuti — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.